EGFR and neoplasm: Possible explanations include involvement of additional ErbB family members not affected by selective EGFR inhibitors, activation of other growth factor pathways such that EGFR blockade is insufficient to induce tumour regression, and changes in apoptotic components that prevent cell death in response to EGFR blockade.